◆英語タイトル:PharmAthene Inc (PIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013566
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
PharmAthene Inc (PharmAthene) is a pharmaceutical company that develops and commercializes medical counter measures to biological and chemical weapons. The company’s products include recombinant protective antigen anthrax vaccine, human monoclonal antibody antitoxin and recombinant BChE bioscavenger. Its products are used for treatment of anthrax, and nerve agent poisoning. PharmAthene serves in markets of biodefense, US civilian, military, and non-US markets. The company collaborates with various pharma and research companies across the world. It markets its products through its distributors across the world. PharmaAthene is headquartered in Annapolis, Maryland, the US.
PharmAthene Inc (PIP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PharmAthene Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PharmAthene Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 10
Merger 11
Altimmune Merges with PharmAthene in Reverse Merger Transaction 11
Licensing Agreements 13
PharmAthene Enters Into Licensing Agreement With Percivia For PER.C6 Cell Line 13
Equity Offering 14
PharmAthene to Raise Additional USD30 Million in Public Offering of Shares 14
PharmAthene Completes Registered Direct Offering Of US$6.5 Million 15
PharmAthene Inc – Key Competitors 16
PharmAthene Inc – Key Employees 17
PharmAthene Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
May 03, 2017: PharmAthene Reports First Quarter 2017 Financial and Operational Results 19
Mar 14, 2017: PharmAthene Reports Year-End 2016 Financial and Operational Results 20
Nov 04, 2016: PharmAthene Reports Third Quarter 2016 Financial and Operational Results 21
Aug 04, 2016: PharmAthene Reports Second Quarter 2016 Financial and Operational Results 22
May 09, 2016: PharmAthene Reports First Quarter 2016 Financial and Operational Results 24
Mar 11, 2016: PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA 25
Corporate Communications 26
Jul 08, 2016: PharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline 26
Legal and Regulatory 27
Nov 16, 2016: PharmAthene Receives Final Payment from SIGA of $83.9 Million 27
Apr 13, 2016: PharmAthene Reports Court Approval of SIGA Reorganization Plan to Exit from Bankruptcy 28
Other Significant Developments 29
Sep 16, 2016: PharmAthene Announces Receipt of Payments from SIGA 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
PharmAthene Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PharmAthene Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PharmAthene Inc, Deals By Therapy Area, 2011 to YTD 2017 8
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 10
Altimmune Merges with PharmAthene in Reverse Merger Transaction 11
PharmAthene Enters Into Licensing Agreement With Percivia For PER.C6 Cell Line 13
PharmAthene to Raise Additional USD30 Million in Public Offering of Shares 14
PharmAthene Completes Registered Direct Offering Of US$6.5 Million 15
PharmAthene Inc, Key Competitors 16
PharmAthene Inc, Key Employees 17
PharmAthene Inc, Subsidiaries 18